Literature DB >> 17101455

Iron dysregulation in Friedreich ataxia.

Robert B Wilson1.   

Abstract

Friedreich ataxia is the most common hereditary ataxia. The signs and symptoms of the disorder derive from decreased expression of the protein frataxin, which is involved in iron metabolism. Frataxin chaperones iron for iron-sulfur cluster biogenesis and detoxifies iron in the mitochondrial matrix. Decreased expression of frataxin is associated with impairments of iron-sulfur cluster biogenesis and heme synthesis, as well as with mitochondrial dysfunction and oxidative stress. Compounds currently in clinical trials are directed toward improving mitochondrial function and lessening oxidative stress. Iron chelators and compounds that increase frataxin expression are under evaluation. Further elucidation of frataxin's function should lead to additional therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101455     DOI: 10.1016/j.spen.2006.08.005

Source DB:  PubMed          Journal:  Semin Pediatr Neurol        ISSN: 1071-9091            Impact factor:   1.636


  18 in total

Review 1.  Mitochondrial medicine for aging and neurodegenerative diseases.

Authors:  P Hemachandra Reddy
Journal:  Neuromolecular Med       Date:  2008-06-20       Impact factor: 3.843

2.  A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia.

Authors:  Eric C Deutsch; Avni B Santani; Susan L Perlman; Jennifer M Farmer; Catherine A Stolle; Michael F Marusich; David R Lynch
Journal:  Mol Genet Metab       Date:  2010-07-08       Impact factor: 4.797

Review 3.  Pharmacology of iron transport.

Authors:  Shaina L Byrne; Divya Krishnamurthy; Marianne Wessling-Resnick
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-09-27       Impact factor: 13.820

Review 4.  Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia.

Authors:  Rachael A Vaubel; Grazia Isaya
Journal:  Mol Cell Neurosci       Date:  2012-08-11       Impact factor: 4.314

Review 5.  Pharmacotherapy for Friedreich ataxia.

Authors:  Amy Y Tsou; Lisa S Friedman; Robert B Wilson; David R Lynch
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy.

Authors:  Daniele Marmolino; Fabio Acquaviva; Michele Pinelli; Antonella Monticelli; Imma Castaldo; Alessandro Filla; Sergio Cocozza
Journal:  Cerebellum       Date:  2008-12-23       Impact factor: 3.847

Review 7.  Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling.

Authors:  Eva-Maria Hanschmann; José Rodrigo Godoy; Carsten Berndt; Christoph Hudemann; Christopher Horst Lillig
Journal:  Antioxid Redox Signal       Date:  2013-03-28       Impact factor: 8.401

8.  Hydrogen peroxide scavenging rescues frataxin deficiency in a Drosophila model of Friedreich's ataxia.

Authors:  Peter R Anderson; Kim Kirby; William C Orr; Arthur J Hilliker; John P Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-09       Impact factor: 11.205

Review 9.  Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.

Authors:  Daniele Marmolino; Fabio Acquaviva
Journal:  Cerebellum       Date:  2009-01-23       Impact factor: 3.847

10.  Molecular and clinical investigation of Iranian patients with Friedreich ataxia.

Authors:  Mohammad Hossein Salehi; Massoud Houshmand; Omid Aryani; Behnam Kamalidehghan; Elham Khalili
Journal:  Iran Biomed J       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.